MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

0.99 -1

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.96

Max

1.01

Belangrijke statistieken
By Trading Economics
Inkomsten	1.8M -32M
Verkoop	-166K 1.7M
EPS	-0.27
Winstmarge	-1,852.384
Werknemers	181
EBITDA	7.9M -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+400% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-4.6M 121M
Vorige openingsprijs	1.99
Vorige sluitingsprijs	0.99

Nieuwssentiment

By Acuity

55%

45%

310 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.9101 / 1.14 Steun & Weerstand

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 dec 2025, 22:03 UTC

Belangrijke Marktbewegers

Mining Stocks Slip Near the End of Stellar Year

29 dec 2025, 15:57 UTC

Belangrijke Marktbewegers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Decline; Yen in Focus -- Market Talk

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Operate From Singapore

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dec 2025, 23:37 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Integrate Manus Service Into Products

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dec 2025, 23:35 UTC

Acquisities, Fusies, Overnames

Manus to Join Meta Platforms

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Raise Values Kraken at US$8.65 Billion

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin's Kraken Stake to Remain at 22.7%

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin: Additional Interest Offsets Dilution From Raise

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dec 2025, 20:22 UTC

Marktinformatie

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dec 2025, 20:02 UTC

Acquisities, Fusies, Overnames

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dec 2025, 17:36 UTC

Marktinformatie

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

400% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD 400%

Hoogste 8 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

310 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.